TW202204422A - 抗tmprss6抗體及其用途 - Google Patents

抗tmprss6抗體及其用途 Download PDF

Info

Publication number
TW202204422A
TW202204422A TW110112433A TW110112433A TW202204422A TW 202204422 A TW202204422 A TW 202204422A TW 110112433 A TW110112433 A TW 110112433A TW 110112433 A TW110112433 A TW 110112433A TW 202204422 A TW202204422 A TW 202204422A
Authority
TW
Taiwan
Prior art keywords
seq
tmprss6
antibody
amino acid
acid sequence
Prior art date
Application number
TW110112433A
Other languages
English (en)
Chinese (zh)
Inventor
杜欣
陳布新
玉 王
Original Assignee
美商邁威（美國）生物治療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商邁威（美國）生物治療有限公司 filed Critical 美商邁威（美國）生物治療有限公司
Publication of TW202204422A publication Critical patent/TW202204422A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW110112433A 2020-04-07 2021-04-06 抗tmprss6抗體及其用途 TW202204422A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063006695P 2020-04-07 2020-04-07
US63/006,695 2020-04-07
US202163158265P 2021-03-08 2021-03-08
US63/158,265 2021-03-08

Publications (1)

Publication Number Publication Date
TW202204422A true TW202204422A (zh) 2022-02-01

Family

ID=75888147

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110112433A TW202204422A (zh) 2020-04-07 2021-04-06 抗tmprss6抗體及其用途

Country Status (9)

Country Link
US (3) US12215170B2 (OSRAM)
EP (1) EP4126220A1 (OSRAM)
JP (1) JP7813234B2 (OSRAM)
KR (1) KR20230007368A (OSRAM)
CN (1) CN115243762A (OSRAM)
AU (1) AU2021251087A1 (OSRAM)
CA (1) CA3174339A1 (OSRAM)
TW (1) TW202204422A (OSRAM)
WO (1) WO2021207072A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230295345A1 (en) * 2020-04-07 2023-09-21 Mabwell Therapeutics, Inc. Anti-tmprss6 antibodies and uses thereof
AU2021251087A1 (en) 2020-04-07 2022-12-01 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
AU2022274888A1 (en) * 2021-05-11 2023-12-07 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
CN120752046A (zh) * 2022-11-25 2025-10-03 迈威(美国)生物治疗有限公司 抗tmprss6抗体及其用途
EP4688867A2 (en) * 2023-04-04 2026-02-11 Disc Medicine, Inc. Anti-tmprss6 antibodies and uses thereof
AU2024243972A1 (en) * 2023-04-06 2025-10-23 Memorial Hospital For Cancer And Allied Diseases Il-10 receptor antibodies and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US20050054027A1 (en) 2003-09-09 2005-03-10 Irm Llc Modulators of transmembrane protease serine 6
GB0614201D0 (en) 2006-07-18 2006-08-23 Univ Cardiff Matriptase-2
AR065083A1 (es) * 2007-02-02 2009-05-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
WO2013070786A1 (en) * 2011-11-07 2013-05-16 Isis Pharmaceuticals, Inc. Modulation of tmprss6 expression
AR093620A1 (es) 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
DE112014005975T5 (de) 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
WO2016071701A1 (en) * 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
CA3119498A1 (en) * 2015-07-31 2017-02-09 Medimmune Limited Methods for treating hepcidin-mediated disorders
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
CA3162880A1 (en) 2019-11-29 2021-06-03 Kymab Limited Treatment for physiological iron overload
AU2021251087A1 (en) 2020-04-07 2022-12-01 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
BR112023022284A2 (pt) 2021-04-26 2023-12-26 Alnylam Pharmaceuticals Inc Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma
AU2022265493A1 (en) 2021-04-27 2023-09-21 Silence Therapeutics Gmbh Sirna targeting tmprss6 for the treatment of myeloproliferative disorders

Also Published As

Publication number Publication date
EP4126220A1 (en) 2023-02-08
JP2023520969A (ja) 2023-05-23
JP7813234B2 (ja) 2026-02-12
CA3174339A1 (en) 2021-10-14
AU2021251087A1 (en) 2022-12-01
WO2021207072A1 (en) 2021-10-14
CN115243762A (zh) 2022-10-25
US20230203196A1 (en) 2023-06-29
US20230348623A1 (en) 2023-11-02
US12215170B2 (en) 2025-02-04
KR20230007368A (ko) 2023-01-12
US20250304719A1 (en) 2025-10-02
US11866513B2 (en) 2024-01-09

Similar Documents

Publication Publication Date Title
US11866513B2 (en) Anti-TMPRSS6 antibodies and uses thereof
US20240002488A1 (en) Method of treating or preventing liver conditions
CN110381988A (zh) 使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法
MX2014010060A (es) Anticuerpos contra la endotelina 1 grande (et - 1 grande) y sus usos.
EP3220952A1 (en) Method of treating or preventing stroke
JP7709436B2 (ja) 生理学的鉄過剰の処置
US20230295345A1 (en) Anti-tmprss6 antibodies and uses thereof
US10654925B2 (en) Anti-marinobufagenin antibodies and uses thereof
US10975159B2 (en) Compounds binding human CD160 and uses thereof
US20250136718A1 (en) Anti-tmprss6 antibodies and uses thereof
CN118078985A (zh) 抗tmprss6抗体及其用途
KR20250128393A (ko) 항-tmprss6 항체 및 그의 용도
HK40104812A (zh) 抗tmprss6抗体及其用途
KR20180095083A (ko) 응고제로서 사용하기 위한 당단백질 v 억제제
HK40079278A (en) Anti-tmprss6 antibodies and uses thereof
RU2790023C2 (ru) Способы лечения заболевания с применением ингибиторов костного морфогенетического белка 6 (вмр6)
WO2024222868A1 (zh) 抗tf抗体和抗tf抗体-药物偶联物及其医药用途
CN121002065A (zh) 抗igf1r抗体及其用途